API change not reported during dossier submission – preventing PQ suspension


Published on 29/01/2026

Managing Unreported API Changes During Dossier Submission to Prevent PQ Suspension

In the dynamic landscape of pharmaceutical manufacturing and regulatory compliance, the failure to report Active Pharmaceutical Ingredient (API) changes during dossier submissions poses significant risks. This situation can lead to delays, compliance issues, and even suspension of Prequalification (PQ) status by WHO. In the following sections, we provide a structured approach to identifying symptoms, understanding causes, and implementing effective controls to address unreported API changes.

If you want a complete overview with practical prevention steps, see this WHO Prequalification (PQ).

This playbook will empower stakeholders across production, quality control (QC), quality assurance (QA), engineering, and regulatory affairs (RA) to act promptly in case of detected discrepancies. Through actionable steps, you’ll be equipped to enhance your inspection readiness, ensure compliance with GMP frameworks, and maintain the integrity of your submission documentation.

Symptoms/Signals on the Floor or in the Lab

Recognizing

the early indicators of unreported API changes is crucial. Symptoms may vary depending on the stage of the manufacturing process, but here are common signs to monitor:

  • Inconsistent Product Performance: Variations in potency, dissolution rates, or stability may signal formulation inconsistencies due to unreported changes.
  • Unexpected Batch Rejections: A higher than normal rate of batch failures during QC testing often correlates with undocumented API modifications.
  • Deviation Records: Frequent deviation reports associated with specific APIs can indicate awareness of changes that have not been communicated in submissions.
  • Feedback from Regulatory Authorities: Requests for clarification or additional information can serve as early warning signs of potential concerns.
  • Change in Supplier or Material Quality: Regulatory changes in supplier qualifications may give rise to risks if not reported in the dossier adequately.

Likely Causes

Understanding the underlying causes of unreported API changes can assist in formulating a timely response. These causes can be categorized as follows:

1. Materials

  • Changes in raw material sourcing without proper documentation.
  • Substantiation of material quality profiles that were not communicated to the regulatory body.

2. Method

  • Modifications in manufacturing processes that reduce quality or alter product specifications.
  • Adjustment in analytical methods used for API testing that do not align with controls established in previous submissions.
Pharma Tip:  CAPA effectiveness doubted during requalification – documentation gaps reviewers flag

3. Machine

  • Equipment used for processing APIs not aligned with originally specified capacity or functionalities.
  • Lack of validation for new equipment implementing unchanged processes can result in unanticipated results.

4. Man

  • Insufficient training or oversight of personnel leading to unwarranted API modifications.
  • Communication gaps between departments, especially during change control procedures.

5. Measurement

  • Inaccurate or insufficient testing of API characteristics affecting ability to recognize changes.
  • Incorrect data logging or trend analysis processes complicating identification of significant deviations.

6. Environment

  • Environmental conditions leading to unexpected changes in API stability.
  • Poor maintenance or monitoring of controlled environments impacting the quality of stored APIs.

Immediate Containment Actions (first 60 minutes)

Upon discovery of an unreported API change, the first step is to initiate containment measures to mitigate potential risk:

  1. Cease Production: Immediately halt production processes that utilize the implicated APIs to prevent the release of non-compliant products.
  2. Alert Quality Assurance: Notify the QA team to initiate thorough assessments of impacted batch records and logs.
  3. Review Documentation: Conduct a rapid review of the associated documentation, including all submissions to regulatory bodies, to identify gaps.
  4. Stakeholder Communication: Engage relevant stakeholders—Production, QA, RA, and Engineering—to report findings and mobilize the investigation.
  5. Establish a Containment Plan: Outline preliminary actions to manage immediate consequences, including temporary holds on affected stocks or batch dispositions.

Investigation Workflow (data to collect + how to interpret)

A robust investigation workflow is essential for effectively addressing unreported API changes:

  1. Data Collection: Gather all relevant data, including batch production records, testing results, and communication logs. This should include both qualitative and quantitative data sources.
  2. Documentation Review: Assess all submissions made to regulatory bodies to identify discrepancies between the actual API used and those documented.
  3. Process Mapping: Create a flowchart of the manufacturing process confirming where, when, and how changes may have occurred.
  4. Root Cause Examination: Utilize tools such as 5-Whys and Fishbone diagrams to derive the sequence of events leading to undisclosed API changes.
  5. Data Interpretation: Examine trends and anomalies; correlate findings to map to the likely cause categories (Materials, Method, etc.).

Root Cause Tools (5-Why, Fishbone, Fault Tree) and when to use which

Utilizing appropriate root cause analysis tools streamlines the investigation process and supports a deeper understanding of the failure mode:

  • 5-Why Analysis: Optimal for isolating specific issues quickly; especially useful when addressing questions about caused defects in a straightforward manner.
  • Fishbone Diagram (Ishikawa): Best employed when multiple potential causes need to be identified and categorized, benefitting from group brainstorming sessions.
  • Fault Tree Analysis: Useful for analyzing complex failure events where different paths can lead to the same unfortunate outcome; beneficial for high-risk or multifaceted investigations.
Pharma Tip:  Stability data gaps during dossier submission – documentation gaps reviewers flag

CAPA Strategy (correction, corrective action, preventive action)

Once the root cause is identified, developing a comprehensive Corrective and Preventive Action (CAPA) plan is essential:

  1. Correction: Take immediate actions to rectify the situation, such as disposal or processing of affected batches in compliance with regulatory guidelines.
  2. Corrective Action: Implement changes to prevent recurrence, which may include modifying documentation practices, enhancing training requirements for staff, or updating ISO-controlled procedures.
  3. Preventive Action: Establish an ongoing monitoring system to ensure compliance, such as regular audits, SOP updates, and enhanced data integrity checks.

Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

Integrating control strategies is pivotal in maintaining compliance and minimizing the risk of future incidents:

  • Statistical Process Control (SPC): Implement SPC methods to monitor critical parameters in real-time, ensuring all process variations are controlled within set limits.
  • Regular Sampling: Increase the frequency of sampling and testing for APIs during production runs to ensure quality and compliance.
  • Alarms and Alerts: Set up alarm systems to trigger when process deviations occur, allowing for immediate corrective measures.
  • Verification Processes: Routinely verify documentation accuracy against the actual API usage, ensuring alignment with regulatory expectations.

Validation / Re-qualification / Change Control impact (when needed)

Any unreported API changes may necessitate a reassessment of validation and change control measures:

  • Validation Reassessment: Depending on the significance of the change, revisit validation protocols to ensure all processes remain compliant with GMP standards.
  • Re-qualification Needs: If equipment or systems involved in API production are altered, performing re-qualification checks becomes critical to prevent compliance lapses.
  • Change Control Protocols: Review and reinforce change control processes to ensure all future alterations to APIs are thoroughly documented, communicated, and approved by regulatory bodies.

Inspection Readiness: what evidence to show (records, logs, batch docs, deviations)

Being inspection-ready after an incident of unreported changes requires meticulous documentation to demonstrate compliance:

Related Reads

  • Records and Logs: Maintain detailed logs of all investigations and CAPA activities, including timelines, responsible parties, and actions taken.
  • Batch Documentation: Ensure all batch records accurately reflect the API used, any deviations, and corrective actions implemented.
  • Deviation Reports: Document all identified deviations and how they were addressed; this incorporates lessons learned and paths forward.
  • Communication Records: Retain evidence of communications with regulatory authorities and internal stakeholders concerning findings and actions taken.
Pharma Tip:  PQ dossier deficiency during dossier submission – PQ assessment risk and mitigation

FAQs

What should I do if unreported API changes are identified post-submission?

Immediately halt all potentially affected production, notify QA and RA teams, and initiate an investigation while assessing potential risks and impacts on previously approved submissions.

How can I best document changes made to APIs for submission?

Establish a rigorous documentation system that includes detailed description of all API characteristics, supplier information, and any changes made, ensuring compliance with submission regulations.

What regulatory bodies must be notified of API changes?

Typically, any changes must be communicated to FDA, EMA, or relevant national regulatory bodies, depending on the markets you are operating within.

How often should we review our change control processes?

Regular reviews should occur at least annually, though more frequent assessments are recommended following any significant incidents or changes in policy/protocols.

Is there a recommended timeframe for conducting investigations into API changes?

Investigations should begin immediately upon awareness of an issue, ideally launched within the first 24 hours, followed by completion of initial findings shortly thereafter.

What role does validation play in managing API changes?

Validation ensures that any changes to APIs do not adversely affect the product quality and compliance with GMP; it is vital to validate any new processes or equipment prior to their use.

When should a CAPA be submitted to the regulatory authorities?

A CAPA should be submitted once all root causes are identified, corrective actions defined, and when there is potential non-compliance that could impact product marketing or patient safety.

Can unreported API changes affect our existing inventory?

Yes, any unreported changes can lead to questions regarding the quality and efficacy of existing inventory, potentially resulting in recalls or product withdrawals.

What are the long-term impacts of failing to report API changes?

Long-term impacts can include regulatory non-compliance, loss of PQ status, reputational damage, and legal ramifications related to product liability or marketed products.

How can our organization prevent unreported changes in the future?

Enhance internal communication channels and training on regulatory compliance, invest in robust documentation practices, and establish strict change control and review protocols.

Is training necessary for all employees involved in API management?

Yes, comprehensive training for all staff involved is essential to ensure understanding of regulatory requirements and effectiveness in handling API changes.

How can I ensure that our documentation meets inspection standards?

Regularly audit documentation processes against regulatory guidelines, conduct mock inspections, and keep detailed records that accurately reflect all API-related activities.